Session Details

S054 What's New in Dermatopathology

Mon, Mar 22, 1:00 PM - 4:00 PM
3 CME Available Symposium

DESCRIPTION

This symposium provides information regarding advances in key areas of dermatopathology. Cutaneous neoplasia, inflammatory skin disease, molecular techniques, computer assisted diagnosis/artificial intelligence, translational research, and cutaneous infections will be covered. New this year will be an update on reimbursement and payer-related issues. Attendees will leave the session with updated knowledge in dermatopathology.

LEARNING OBJECTIVES

1.

Describe new advances in cutaneous neoplasia, including melanocytic tumors and adnexal neoplasms

2.

Discuss recent developments in diagnosing inflammatory skin disease, immune bullous disorders, and cutaneous drug reactions

3.

Describe recent developments in reimbursement and payer-related issues in the field of dermatopathology

DIRECTOR

Anisha Patel, MD, FAAD

Anisha Patel, MD, FAAD

UT MD Anderson Cancer Center

SPEAKERS

Shruti Agrawal, MD, FAAD

Shruti Agrawal, MD, FAAD

Ryan Walter Hick, MD, FAAD

Ryan Walter Hick, MD, FAAD

ProPath Dermatopathology

Angela Juan Jiang, MD, FAAD

Angela Juan Jiang, MD, FAAD

Oregon Health & Science University

Kiran Motaparthi, MD, FAAD

Kiran Motaparthi, MD, FAAD

Jeffrey P. North, MD, FAAD

Jeffrey P. North, MD, FAAD

Iwei Yeh, MD, PhD, FAAD

Iwei Yeh, MD, PhD, FAAD

University of California, San Francisco

DISCLOSURES

Shruti Agrawal, MD, FAAD

No financial relationships exist with ineligible companies.

Ryan Walter Hick, MD, FAAD

PP Capital – Stockholder(No Compensation Received); Sonic Healthcare – Stockholder(No Compensation Received); Stingray Therapeutics – Stockholder(No Compensation Received);

Angela Juan Jiang, MD, FAAD

No financial relationships exist with ineligible companies.

Kiran Motaparthi, MD, FAAD

No financial relationships exist with ineligible companies.

Jeffrey P. North, MD, FAAD

Johnson & Johnson Pharmaceutical Research & Development – Consultant (1099 relationship)(Fees);

Anisha Patel, MD, FAAD

Astellas Pharma US, Inc – Consultant (1099 relationship)(Fees); Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); Deciphera Pharmaceuticals, Inc. – Consultant (1099 relationship)(Fees); EMD Serono – Advisory Board(Fees); Erasca – Consultant (1099 relationship)(Fees); FBIO Acquisition Corp LXI – Consultant (1099 relationship)(Stock); Hoth Therapeutics – Investigator(Grants/Research Funding); IDEOlogy Health – Consultant (1099 relationship)(Fees); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Revolution Medicines – Advisory Board(Fees); Roche Pharma – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);

Iwei Yeh, MD, PhD, FAAD

Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals Inc – Advisory Board(Honoraria);